# Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma

> **NCT01178658** · PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Busulfan, etoposide, cytarabine, and melphalan

## Key facts

- **NCT ID:** NCT01178658
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-07
- **Primary completion:** 2014-12
- **Final completion:** —
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2014-08-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01178658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01178658, "Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01178658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*